Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Brian M Calimlim

10PUBLICATIONS

51CO-AUTHORS

Environmental epidemiologyGene and molecular therapyAllergyEpidemiological methodsMajor global burdens of disease

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|Jun 02, 2025

Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis.

Eric L Simpson, Jonathan I Silverberg, Vimal H Prajapati

|May 02, 2024

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).

Eric L Simpson, Vimal H Prajapati, Yael A Leshem

|Mar 26, 2024

Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).

Jonathan I Silverberg, Melinda J Gooderham, Amy S Paller

|Dec 18, 2023

Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis®.

Jonathan I Silverberg, Marjolein de Bruin-Weller, Brian M Calimlim

|Sep 05, 2023

Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.

Kilian Eyerich, Melinda J Gooderham, Juan Francisco Silvestre

|Aug 01, 2023

Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.

Emma Guttman-Yassky, Jonathan I Silverberg, Diamant Thaçi

Pageof 2

Frequent Collaborators

7 joint publications

Jonathan I Silverberg

3 joint publications

Andrew M Platt

3 joint publications

Jacob P Thyssen

3 joint publications

Wan-Ju Lee

3 joint publications

Eric L Simpson

3 joint publications

Marjolein S de Bruin-Weller

3 joint publications

Kilian Eyerich

2 joint publications

Melinda J Gooderham

2 joint publications

Henrique D Teixeira

2 joint publications

Barry Ladizinski

Frequent Collaborators

7 joint publications

Jonathan I Silverberg

3 joint publications

Andrew M Platt

3 joint publications

Jacob P Thyssen

3 joint publications

Wan-Ju Lee

Top Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on : Apr 07, 2023

See more related videos

Top Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on : Apr 07, 2023

See more related videos